Foundayo (orforglipron)vsHenry Meds Compounded Oral Semaglutide (Dissolvable Tablets / Drops)

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist. Unlike semaglutide (a peptide that degrades in the gut and needs special absorption tricks), this small molecule is absorbed normally, so it can be taken without food or water timing rules. By activating the GLP-1 receptor it raises glucose-dependent insulin secretion, slows gastric emptying, and dampens appetite.

The active ingredient is semaglutide, the same GLP-1 receptor agonist found in branded products, prepared by a compounding pharmacy as a dissolvable tablet or sublingual drop. The intent is absorption through the tissues of the mouth to bypass the digestive breakdown that limits swallowed peptide pills, though real-world absorption from these routes is reported to be low and variable.

In the phase 3 ATTAIN-1 trial (NEJM, 2025; n=3,127 adults with obesity without diabetes), mean weight change at week 72 was -7.5% (6 mg), -8.4% (12 mg), and -11.2% (36 mg) versus -2.1% for placebo; Lilly also reports up to ~12.4% in adherence-based analyses. Nearly 60% on the highest dose lost at least 10% of body weight.

Semaglutide as a drug class has strong efficacy data, but there are no large-scale outcomes trials for compounded sublingual or oral-troche formulations specifically, and reported bioavailability of sublingual routes is only about 3-10%. Expected weight loss is therefore less predictable than with FDA-approved oral semaglutide; results depend heavily on the formulation, dose actually absorbed, and adherence.

Side effects are predominantly gastrointestinal (nausea, vomiting, diarrhea, constipation), mostly mild to moderate and concentrated during the titration period. As with the GLP-1 class, rare serious risks such as pancreatitis can occur. Review your medical history with a licensed provider before starting.

Expect the usual GLP-1 GI effects: nausea, diarrhea, vomiting, and constipation, often worst early on. An added concern with compounded products is potential variability in potency and purity, since these are not FDA-reviewed. Rare serious risks like pancreatitis exist across the class. Discuss your full history with a licensed provider and report problems promptly.

As of September 2026, LillyDirect's regular self-pay price for Foundayo is $149/month for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg; the 2.5 mg dose is temporarily reduced to $149/month through December 31, 2026. Eligible commercially insured patients may pay less with a savings card. Confirm current pricing at LillyDirect.

As of May 2026, reported all-inclusive pricing for Henry's oral/sublingual semaglutide ranges roughly $149-$249/month (covering medication, provider visits, supplies, and shipping), with higher doses adding about $100/month. It is cash-pay only with no insurance accepted. Pricing varies by source and changes over time, so confirm directly with Henry Meds.

For adults with obesity (BMI >=30) or overweight (BMI >=27) with at least one weight-related comorbidity, alongside diet and physical activity. Standard GLP-1 precautions apply, including screening for thyroid cancer history and pancreatitis. A prescription and clinician evaluation are required.

Adults seeking weight management who qualify after a telehealth evaluation and who are comfortable with a compounded (non-FDA-approved) medication. Standard GLP-1 contraindications apply, including personal or family history of medullary thyroid carcinoma or MEN2 and a history of pancreatitis. A prescription is still required.